Back to Search
Start Over
A phase II study of aziridinylbenzoquinone (AZQ) in advanced large bowel carcinoma.
- Source :
-
American journal of clinical oncology [Am J Clin Oncol] 1982 Oct; Vol. 5 (5), pp. 539-40. - Publication Year :
- 1982
-
Abstract
- Aziridinylbenzoquinone (AZQ: NSC-182986), is a quinone derivative which has been shown to have activity in implanted murine tumor systems. Toxicity in small and large animals included hypothermia, diarrhea, anorexia, emesis, weight loss, and gastrointestinal bleeding. In addition, there was myelosuppression and elevated liver function tests. In a phase I study at the Mayo Clinic, dose-limiting toxicity was myelosuppression. Patients with prior radiation therapy or prior chemotherapy were more sensitive to this toxicity. A dose schedule of 27.5 mg/m2 q4 weeks was recommended for patients who had had no previous chemotherapy and 22.5 mg/m2 for previously treated patients or for patients who had had extensive prior radiation therapy. The objective of this study was to determine therapeutic activity for AZQ in patients with advanced colorectal adenocarcinoma.
- Subjects :
- Adult
Aged
Antineoplastic Agents adverse effects
Aziridines adverse effects
Drug Administration Schedule
Drug Evaluation
Female
Humans
Leukopenia chemically induced
Male
Middle Aged
Thrombocytopenia chemically induced
Adenocarcinoma drug therapy
Antineoplastic Agents administration & dosage
Aziridines administration & dosage
Azirines administration & dosage
Benzoquinones
Colonic Neoplasms drug therapy
Rectal Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0277-3732
- Volume :
- 5
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- American journal of clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 7180832